Highest-materiality recent filing
Master Manufacturing Services Agreement executed April 28, 2026, with Emergent BioSolutions Canada Inc. for SAB-142.
All 4 T1D participants on SAB-142 2.5 mg/kg preserved C-peptide; 3 of 4 achieved super responder status with C-peptide above baseline at Day 120.
SAB Biotherapeutics prices $85M public offering of common stock and pre-funded warrants
Priced 19.3M shares at $3.85/share and pre-funded warrants for 2.75M shares at $3.8499 each.
SAB-142 Phase 1 data shows C-peptide preservation in established T1D patients at Day 120
T1D cohort (n=6): 4 treated with SAB-142 (2.5 mg/kg) showed no decline in C-peptide at Day 120; mean values increased above baseline.
SAB Bio appoints David Zaccardelli as Chair and Rita Jain as independent director
David Zaccardelli, Pharm.D., appointed Chair of the Board effective January 5, 2026; led Ohtuvayre launch at Verona Pharma.
SAB Biotherapeutics establishes new $75M ATM equity program via UBS, terminates prior $20M ATM
Entered sales agreement with UBS Securities for at-the-market offering of common stock up to $75 million aggregate offering price.
Shareholders approved increasing plan shares by 24,180,000 to 31,932,466 total; evergreen cap raised to 73,750,000 shares.
Gross proceeds of $175M from sale of Series B convertible preferred stock and warrants; conversion price $1.75 per common share.
Phase 1 trial of SAB-142 met primary safety and PD objectives; generally well-tolerated, no serum sickness or anti-drug antibodies at target dose.
SAB Bio completes Phase 1 healthy-volunteer enrollment; SAB-142 shows no serum sickness at 2.5 mg/kg
Phase 1 trial of SAB-142 for type 1 diabetes completed all planned healthy-volunteer cohorts; no serum sickness observed at target 2.5 mg/kg dose.
FDA clears IND for SAB Biotherapeutics' T1D therapy SAB-142 Phase 1 trial
FDA cleared IND for SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes.
On July 26, 2024, Lucy To, 38, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (“SAB BIO” or the “Company”), with a start date of August 12, 2024.
Mark Conley, who has been serving as Interim Chief Financial Officer since June 4, 2024, will reassume his prior position as the Company’s Vice President of Finance.
On May 30, 2024, Mark Conley, 62, was appointed Interim Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective June 4, 2024.
On May 26, 2024, Michael King, Jr., Chief Financial Officer of the Company, informed the Company that he will resign from his position with the Company, effective June 4, 2024, to pursue another opportunity.
On May 3, 2024, the Nominating and Corporate Governance Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of SAB Biotherapeutics, Inc., a Delaware corporation (the “ Company ”), recommended the appointment of, and the Board subsequently appointed, Dr. Jay S. Skyler to serve as a Class I director of the Company, effective as of May 3, 2024, and to serve until the Company’s 2025 annual meeting of stockholders or until Dr. Skyler’s successor is duly elected and qualified.
Max materiality 0.85 · Median 0.60 · Most common event other_material